Thyroid Cancer Risk Stratification (ATA)

Stratifies differentiated thyroid cancer recurrence risk using ATA 2015 guidelines. Guides extent of surgery, radioiodine (RAI), and surveillance intensity. Not for poorly differentiated or anaplastic thyroid cancer.

Used in: Thyroid Disorders

Score interpretation

ATA Low risk recurrence (<5%) 1

No high- or intermediate-risk feature (ATA 2015).

→ Thyroid lobectomy may suffice for T1-T2 low-risk; no RAI for low-risk; TSH 0.5-2 mU/L suppression target; annual Tg + USS for 5 years

ATA Intermediate risk (5-20%) 2

At least one intermediate-risk feature and no high-risk feature (ATA 2015).

→ Total thyroidectomy; RAI if nodal disease or extrathyroidal extension (Adults: 30-100 mCi; Children: use a children's formulary.); TSH 0.1-0.5 mU/L; 6-monthly Tg + USS; endocrine surgery MDT

ATA High risk (>20% recurrence) 3

At least one high-risk feature (ATA 2015).

→ Total thyroidectomy + therapeutic neck dissection; high-dose RAI (Adults: 100-200 mCi; Children: use a children's formulary.); TSH <0.1 mU/L suppression; whole body RAI scan; 3-monthly surveillance; clinical trial for poorly differentiated/anaplastic

Interpretation bands for the Thyroid Cancer ATA Risk. Apply clinical judgement and local guidance.

References

Curated clinical cross-links plus same-class fallbacks.

Drugs

Pathways

Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.

Score interpretation

References

Related